MetastamiRs: A promising choice for antihepatocellular carcinoma nucleic acid drug development
文献类型：期刊论文
| 作者 | Wu, Liangcai1,4; Bai, Xue1; Xie, Yuan1; Yang, Xiaobo1; Lin, Jianzhen1; Zhu, Chengpei1; Wang, Anqiang1; Zhang, Haohai1; Miao, Ruoyu1; Zhao, Yi1,4 |
| 刊名 | HEPATOLOGY RESEARCH
 |
| 出版日期 | 2017 |
| 卷号 | 47期号:1页码:80-94 |
| 关键词 | hepatocellular carcinoma metastasis microRNA |
| ISSN号 | 1386-6346 |
| DOI | 10.1111/hepr.12737 |
| 文献子类 | Review |
| 英文摘要 | Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide, which can be explained at least in part by its propensity towards metastasis and the limited efficacy of adjuvant therapy. MetastamiRs are miRNAs that promote or suppress migration and metastasis of cancer cells, and their functional status is significantly correlated with HCC prognosis. Unlike targeted therapy, metastamiRs have the potential to target multiple genes and signaling pathways and dramatically suppress cancer metastasis. In this review, we discuss the regulatory role of metastamiRs in the HCC invasion-metastasis cascade. Moreover, Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis has shown that many extensively studied metastamiRs target several critical signaling pathways and these have remarkable therapeutic potential in HCC. The information reviewed here may assist in further anti-HCC miRNA drug screening and development. |
| 学科主题 | Gastroenterology & Hepatology |
| WOS关键词 | HUMAN HEPATOCELLULAR-CARCINOMA ; SUPPRESSES TUMOR-GROWTH ; EPITHELIAL-MESENCHYMAL TRANSITION ; HEPATITIS-C VIRUS ; LIVER-SPECIFIC MICRORNA ; DOWN-REGULATION ; CELL-PROLIFERATION ; HEPATOMA-CELLS ; PROMOTES METASTASIS ; INHIBITS MIGRATION |
| 语种 | 英语 |
| WOS记录号 | WOS:000392432200008 |
| 出版者 | WILEY-BLACKWELL |
| 版本 | 出版稿 |
| 源URL | [http://202.127.25.144/handle/331004/1188]  |
| 专题 | 中国科学院上海生命科学研究院营养科学研究所 |
| 作者单位 | 1.Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Liver Surg, Beijing, Peoples R China; 2.Chinese Acad Med Sci, Peking Union Med Coll Hosp, Ctr Translat Med, 1 Shuaifuyuan, Beijing 100730, Peoples R China; 3.Peking Union Med Coll, 1 Shuaifuyuan, Beijing 100730, Peoples R China; 4.Chinese Acad Sci, Inst Comp Technol, Key Lab Intelligent Informat Proc, Beijing, Peoples R China; 5.CAS MPG Partner Inst Computat Biol, Key Lab Computat Biol, Shanghai, Peoples R China; 6.Harvard Med Sch, Beth Israel Deaconess Med Ctr, Liver Ctr, Brookline, MA USA; 7.Harvard Med Sch, Beth Israel Deaconess Med Ctr, Transplant Inst, Dept Med, Brookline, MA USA; 8.Harvard Med Sch, Beth Israel Deaconess Med Ctr, Transplant Inst, Dept Surg, Brookline, MA USA, |
| 推荐引用方式 GB/T 7714 | Wu, Liangcai,Bai, Xue,Xie, Yuan,et al. MetastamiRs: A promising choice for antihepatocellular carcinoma nucleic acid drug development[J]. HEPATOLOGY RESEARCH,2017,47(1):80-94. |
| APA | Wu, Liangcai.,Bai, Xue.,Xie, Yuan.,Yang, Xiaobo.,Lin, Jianzhen.,...&,.(2017).MetastamiRs: A promising choice for antihepatocellular carcinoma nucleic acid drug development.HEPATOLOGY RESEARCH,47(1),80-94. |
| MLA | Wu, Liangcai,et al."MetastamiRs: A promising choice for antihepatocellular carcinoma nucleic acid drug development".HEPATOLOGY RESEARCH 47.1(2017):80-94. |
入库方式： OAI收割
来源：上海营养与健康研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。